Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PTPRB | P23467 | 1/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8871859 | 1.00 | FFAR1 (0.66) | FFAR1ALDH1A1TRPV1TSHRMEN1 | |
| SCHEMBL27290755 | 0.98 | FFAR1 (0.64) | FFAR1ALDH1A1TRPV1TSHRMEN1 | |
| Bromide SCHEMBL27898131 | 0.98 | FFAR1 (0.64) | FFAR1ALDH1A1TRPV1TSHRMEN1 | |
| SCHEMBL1538733 | 0.90 | KMT2A (0.61) | FFAR1ALDH1A1TRPV1TSHRMEN1 | |
| SCHEMBL5738137 | 0.89 | ALDH1A1 (0.58) | FFAR1ALDH1A1TRPV1TSHRMEN1 | |
| SCHEMBL28094404 | 0.88 | TRPV1 (0.59) | FFAR1ALDH1A1TRPV1TSHRMEN1 | |
| SCHEMBL4608243 | 0.88 | MAPT (0.58) | FFAR1ALDH1A1TRPV1TSHRMEN1 | |
| SCHEMBL5354183 | 0.88 | MAPT (0.58) | FFAR1ALDH1A1TRPV1TSHRMEN1 | |
| SCHEMBL27472434 | 0.87 | TRPV1 (0.58) | FFAR1ALDH1A1TRPV1TSHRMEN1 | |
| SCHEMBL7733006 | 0.85 | TRPV1 (0.56) | FFAR1ALDH1A1TRPV1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569765-A | Preparation method and application of active oxygen response type artificial ion channel | 厦门大学 | 2025-03-07 | — | — | CN | claimed |
| CN-118974013-A | Pyrrolidine compounds | 伊莱利利公司 | 2024-11-15 | — | — | CN | claimed |
| US-20050154011-A1 | Tetrahydroisoquinolnyl sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2005-07-14 | — | — | US | claimed |
| CN-119569765-A | Preparation method and application of active oxygen response type artificial ion channel | 厦门大学 | 2025-03-07 | — | — | CN | disclosed |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| CN-118974013-A | Pyrrolidine compounds | 伊莱利利公司 | 2024-11-15 | — | — | CN | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| WO-2024072178-A1 | COMPOUND FOR TARGETED PROTEIN DEGRADATION, AND USE THEREOF | (주)사이러스테라퓨틱스 | 2024-04-04 | — | — | WO | disclosed |
| EP-3902796-B1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117024371-A | Compound with function of reversing PD-1 drug resistance and application thereof | 中国人民解放军海军军医大学 | 2023-11-10 | — | — | CN | disclosed |
| US-11738000-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | BIOMEDICAL ANALYSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-08-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1185271-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-03-13 | — | — | EP | disclosed |
| CN-1340046-A | Beta-alanine derivatives | MERCK PATENT GMBH (DE) | 2002-03-13 | — | — | CN | disclosed |
| EP-1153014-A2 | BETA-ALANINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-11-14 | — | — | EP | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000076515-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000048996-A2 | β-ALANINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-08-24 | — | — | WO | disclosed |
| US-5610144-A | CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | FFAR1 546/4885ALDH1A1 419/4885TRPV1 3888/4885 |
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | FFAR1 345/4885ALDH1A1 146/4885TRPV1 302/4885 |
| US-20050154011-A1 | Tetrahydroisoquinolnyl sulfamic acids | PTPRS, PTPRJ, PTPRM | FFAR1 839/4885ALDH1A1 999/4885TRPV1 3824/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | FFAR1 509/4885ALDH1A1 455/4885TRPV1 4402/4885 |
| US-11738000-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | WEE2, WEE1, NQO1 | FFAR1 1080/4885ALDH1A1 340/4885TRPV1 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.